echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Leuprolide injection emulsion, a subsidiary of Changchun Hi-Tech Holdings, was approved for clinical use

    Leuprolide injection emulsion, a subsidiary of Changchun Hi-Tech Holdings, was approved for clinical use

    • Last Update: 2022-04-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Changchun Hi-Tech announced that its holding subsidiary Jinsai Pharmaceuticals Leuprolide Injection Emulsion has recently received a drug clinical trial approval notice from NMPA
    .
    According to the "Drug Administration Law of the People's Republic of China" and relevant regulations, after review, the leuprolide injection emulsion accepted on December 30, 2021 meets the relevant requirements for drug registration, and the clinical trial application is approved, namely: an evaluation A clinical study of the safety and efficacy of prorelin injection emulsion in the treatment of advanced prostate cancer
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.